Corteva (CTVA) Aperçu de l'action
Corteva, Inc. opère dans le secteur de l'agriculture. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 3/6 |
| Croissance future | 1/6 |
| Performances passées | 3/6 |
| Santé financière | 5/6 |
| Dividendes | 2/6 |
CTVA Community Fair Values
Create NarrativeSee what 48 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Corteva, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$81.62 |
| Plus haut sur 52 semaines | US$85.63 |
| Plus bas sur 52 semaines | US$60.54 |
| Bêta | 0.57 |
| Variation sur 1 mois | 3.20% |
| Variation sur 3 mois | -0.45% |
| Variation sur 1 an | 9.85% |
| Variation sur 3 ans | 41.46% |
| Variation sur 5 ans | 82.92% |
| Évolution depuis l'introduction en bourse | 228.98% |
Nouvelles et mises à jour récentes
Article d’analyse • Jun 20
Corteva (CTVA) Stock Could Be 13% Undervalued After FMC Herbicide Deal
Why the new FMC partnership matters for Corteva stock Corteva (CTVA) recently signed a multi-year, co-exclusive supply and license agreement with FMC Corporation for rimisoxafen herbicide technology, giving the company another tool in corn and soybean crop protection. The deal covers North and South American markets, includes a US$200 million prepurchase payment from Corteva, and allows both companies to create their own premix formulations. Commercial sales are targeted by the end of the...
Mise à jour du récit • Jun 14
CTVA: Upcoming Spin Focused On Seed And Crop Protection Will Reshape Earnings Mix
Corteva's updated analyst price target edges higher by about $0.14 to roughly $90.05, as analysts refine their assumptions around revenue growth, profit margins and future P/E in light of recent target increases across the Street for the upcoming spin focused on seed and crop protection businesses. Analyst Commentary Recent research updates around Corteva cluster around the upcoming spin of its seed and crop protection businesses, with a series of higher price targets reflecting refreshed views on growth, execution and valuation for what some refer to as "New Corteva." Bullish analysts point to recalibrated assumptions on revenue, margins and P/E, while more cautious voices focus on whether the standalone company can consistently deliver against those expectations once separated.Mise à jour du récit • May 31
CTVA: SpinCo Separation And Biofungicide Collaboration Will Reshape Future Earnings Mix
The analyst price target for Corteva is updated to $89.90 from $86.05 as analysts note that the market is treating "New Corteva" like a no-growth commodity chemical company. They instead highlight expectations for a healthier standalone growth profile, modestly higher profit margins, and a slightly lower assumed future P/E multiple.Seeking Alpha • May 28
Corteva: Two Businesses, One Price
Summary Corteva, Inc. (CTVA) is rated Hold due to valuation concerns ahead of its planned separation into Vylor (Seed) and New Corteva (Crop Protection). DCF analysis implies a share price of $51.95, significantly below the current market price, while SOTP multiples suggest higher value, primarily from Vylor's premium profile. Seed/Vylor is higher-margin and more defensible, while Crop Protection/New Corteva faces cyclical and competitive pressures, impacting future standalone multiples. Key risks include execution of the separation, realization of valuation premiums, and segment-specific challenges such as Vylor's market share and New Corteva's pricing pressure. Read the full article on Seeking AlphaRecent updates
Article d’analyse • Jun 20
Corteva (CTVA) Stock Could Be 13% Undervalued After FMC Herbicide Deal
Why the new FMC partnership matters for Corteva stock Corteva (CTVA) recently signed a multi-year, co-exclusive supply and license agreement with FMC Corporation for rimisoxafen herbicide technology, giving the company another tool in corn and soybean crop protection. The deal covers North and South American markets, includes a US$200 million prepurchase payment from Corteva, and allows both companies to create their own premix formulations. Commercial sales are targeted by the end of the...Mise à jour du récit • Jun 14
CTVA: Upcoming Spin Focused On Seed And Crop Protection Will Reshape Earnings Mix
Corteva's updated analyst price target edges higher by about $0.14 to roughly $90.05, as analysts refine their assumptions around revenue growth, profit margins and future P/E in light of recent target increases across the Street for the upcoming spin focused on seed and crop protection businesses. Analyst Commentary Recent research updates around Corteva cluster around the upcoming spin of its seed and crop protection businesses, with a series of higher price targets reflecting refreshed views on growth, execution and valuation for what some refer to as "New Corteva." Bullish analysts point to recalibrated assumptions on revenue, margins and P/E, while more cautious voices focus on whether the standalone company can consistently deliver against those expectations once separated.Mise à jour du récit • May 31
CTVA: SpinCo Separation And Biofungicide Collaboration Will Reshape Future Earnings Mix
The analyst price target for Corteva is updated to $89.90 from $86.05 as analysts note that the market is treating "New Corteva" like a no-growth commodity chemical company. They instead highlight expectations for a healthier standalone growth profile, modestly higher profit margins, and a slightly lower assumed future P/E multiple.Seeking Alpha • May 28
Corteva: Two Businesses, One Price
Summary Corteva, Inc. (CTVA) is rated Hold due to valuation concerns ahead of its planned separation into Vylor (Seed) and New Corteva (Crop Protection). DCF analysis implies a share price of $51.95, significantly below the current market price, while SOTP multiples suggest higher value, primarily from Vylor's premium profile. Seed/Vylor is higher-margin and more defensible, while Crop Protection/New Corteva faces cyclical and competitive pressures, impacting future standalone multiples. Key risks include execution of the separation, realization of valuation premiums, and segment-specific challenges such as Vylor's market share and New Corteva's pricing pressure. Read the full article on Seeking AlphaArticle d’analyse • May 14
Corteva's (NYSE:CTVA) Performance Is Even Better Than Its Earnings Suggest
Even though Corteva, Inc.'s ( NYSE:CTVA ) recent earnings release was robust, the market didn't seem to notice...Mise à jour du récit • Apr 27
CTVA: Fair Value View Weighs Crop Protection Uncertainty And Planned SpinCo Separation
Corteva's analyst price target has increased by about $2, as analysts cite updated earnings models, a revised fair value of $86.05, a slightly adjusted discount rate, and modest changes to revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Street research on Corteva has been active, with several price target revisions and a mix of ratings changes that give you both supportive and cautious signals to weigh.Mise à jour du récit • Apr 13
CTVA: Fair Value View Balances Crop Protection Risks And Upcoming SpinCo Separation
The analyst price target for Corteva has moved modestly higher to align with a fair value estimate of about $84, as analysts factor in updated earnings models, slightly adjusted revenue growth and profit margin assumptions, and recent price target changes across several firms. Analyst Commentary Recent Street research on Corteva shows a mix of higher price targets and a few rating downgrades, so you are seeing both optimism and caution reflected in the current analyst debate.Mise à jour du récit • Mar 28
CTVA: Crop Protection Uncertainty And SpinCo Separation Will Shape Future Risk Balance
The analyst price target for Corteva has been nudged higher, with a modest fair value uplift to $83.95 as analysts balance a series of recent target increases from multiple firms against more cautious views tied to softer crop protection trends. Analyst Commentary Recent research on Corteva reflects a split view, with several firms lifting price targets while others turn more cautious on near term fundamentals, especially in crop protection.Mise à jour du récit • Mar 12
CTVA: Mixed Crop Protection Outlook And New SpinCo Plan Will Shape Risk Balance
The analyst price target for Corteva edges higher to $83.33 from $82.76, as analysts factor in slightly firmer long term revenue growth and profit margins, while balancing more cautious views on crop protection trends and a modestly lower discount rate. Analyst Commentary Recent research on Corteva reflects a split view, with several firms lifting price targets while others turn more cautious on execution in crop protection.Mise à jour du récit • Feb 26
CTVA: Sector Uncertainty And New Ventures Will Shape Forward Risk Balance
Corteva's analyst fair value estimate has edged up to $82.76 from $82.05 as analysts refine their models and price targets following recent earnings updates and a broad wave of upward target revisions across the Street. Analyst Commentary Recent Street research around Corteva reflects an active debate, with several firms adjusting price targets and a mix of upgrades and downgrades around the latest earnings update.Mise à jour du récit • Feb 11
CTVA: Mixed Sector Backdrop And New Ventures Will Shape Future Prospects
Corteva's analyst fair value estimate has increased to $82.05 from $78.43 as analysts factor in slightly stronger revenue growth assumptions, a higher future P/E multiple, and a modestly lower discount rate, even as projected profit margins are trimmed. Analyst Commentary Recent Street research on Corteva is mixed, with several bullish analysts lifting price targets while a few high profile firms turn more cautious.Mise à jour du récit • Jan 26
CTVA: Seed And Crop Protection Split Will Shape Balanced Future Prospects
Narrative Update Analysts have modestly raised their price expectations for Corteva, with the updated fair value estimate moving by about US$0.48 per share. This reflects slightly adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E, and is supported by recent target increases from several firms.Mise à jour du récit • Jan 11
CTVA: Planned Seed And Pesticide Split Will Support Future Earnings Power
Analysts lifted their blended fair value estimate for Corteva by about $0.19 to roughly $77.95 per share, reflecting updated price targets that factor in a mixed backdrop for chemicals and agriculture but continued confidence in the company’s ability to increase earnings. Analyst Commentary Recent research on Corteva reflects a mix of optimism and caution, with price targets clustered in the mid to high US$70s and one outlier in the low US$80s.Mise à jour du récit • Dec 18
CTVA: Planned Seed And Pesticide Split Will Unlock Future Earnings Power
The analyst price target for Corteva has been nudged higher by approximately $0.05 to about $77.76, as analysts factor in a slightly lower discount rate and modestly improved long term growth expectations, despite broadly cautious sector commentary and recent target reductions. Analyst Commentary Street research on Corteva reflects a divided but generally constructive view, with price targets drifting lower but ratings remaining skewed toward positive as investors reassess the company’s post breakup trajectory and near term earnings backdrop.Mise à jour du récit • Dec 03
CTVA: Planned Seed And Pesticide Split Will Unlock Future Earnings Power
Our analyst price target for Corteva has been trimmed modestly in line with recent Street moves, as analysts factor in lower sector multiples and near term earnings uncertainty around the planned split, while still recognizing the company’s intact innovation engine and long term earnings growth potential. Analyst Commentary Street views on Corteva have become more bifurcated following the announced split, with valuation targets reset lower but ratings broadly supportive of the long term strategic rationale and earnings power.Article d’analyse • Nov 26
A Look At The Fair Value Of Corteva, Inc. (NYSE:CTVA)
Key Insights Corteva's estimated fair value is US$63.85 based on 2 Stage Free Cash Flow to Equity Current share price...Mise à jour du récit • Nov 19
CTVA: Upcoming Seed And Pesticide Split Will Unlock Shareholder Value
The analyst consensus price target for Corteva has been modestly reduced, slipping from approximately $77.86 to $77.71. Analysts reflect more cautious expectations for earnings growth in light of a mixed agricultural outlook and anticipated impacts from the company's planned business split.Mise à jour du récit • Nov 05
CTVA: Share Split Will Drive Shareholder Value Unlocking Amid Ongoing Business Realignment
Analysts have modestly reduced their average price target for Corteva by approximately $1.20. They cite a more cautious outlook amid challenging crop protection conditions and the company's recent announcement to split into two separate businesses.Mise à jour du récit • Oct 22
Analysts Offer Mixed Views as Corteva Eyes Split and Updates Guidance Amid Modest Valuation Shift
Analysts have modestly reduced their price target for Corteva by about $0.76 to $79.05. They cite uncertainty regarding the company’s planned split and the retention of legacy liabilities, though fundamentals and growth remain largely stable.Mise à jour du récit • Oct 08
High-Yield Seed Demand And Eco Policies Will Transform Agriculture
Corteva's analyst price target has been modestly reduced by $0.95 per share. Analysts cite continued uncertainty around the planned corporate split and complex crop protection market dynamics.Mise à jour du récit • Sep 04
High-Yield Seed Demand And Eco Policies Will Transform Agriculture
Analysts maintained their price target for Corteva at $80.76, citing margin expansion and EBITDA growth driven by successful innovation, favorable market fundamentals, and strong execution. Analyst Commentary Ongoing cost reductions, successful innovation, and strong execution are driving margin expansion and double-digit EBITDA growth.Article d’analyse • Aug 26
Corteva's (NYSE:CTVA) Shareholders Will Receive A Bigger Dividend Than Last Year
Corteva, Inc. ( NYSE:CTVA ) will increase its dividend from last year's comparable payment on the 15th of September to...Article d’analyse • Aug 01
Corteva's (NYSE:CTVA) Shareholders Will Receive A Bigger Dividend Than Last Year
Corteva, Inc. ( NYSE:CTVA ) will increase its dividend on the 15th of September to $0.18, which is 5.9% higher than...Article d’analyse • Jul 28
Investors Interested In Corteva, Inc.'s (NYSE:CTVA) Earnings
With a price-to-earnings (or "P/E") ratio of 43.9x Corteva, Inc. ( NYSE:CTVA ) may be sending very bearish signals at...Article d’analyse • Jul 14
We Think Corteva (NYSE:CTVA) Can Stay On Top Of Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Apr 21
Corteva: Upgraded To Strong Buy On Tariffs, Currency Tailwinds, Strong Guidance
Summary Upgrading Corteva from Buy to Strong Buy due to macro conditions, including tariff-induced supply shocks, rising commodity prices, and currency tailwinds. Corteva's diversified supply chain and local production in seeds position it to benefit from regionalization and potential inflationary pressures in the agricultural sector. Strong Q4 earnings, record operating EBITDA margin, and robust free cash flow support the bullish outlook, with significant shareholder returns through dividends and buybacks. Improved valuation at 20x forward earnings, solid balance sheet, and technical indicators suggest potential for further upside in the current market environment. Read the full article on Seeking AlphaSeeking Alpha • Mar 30
Pure Market Inefficiency In Corteva Preferreds Pricings
Summary This article explores a market inefficiency in fixed-income securities, specifically between Corteva's $4.50 and $3.50 Series Cumulative Preferred Stocks. We identified an arbitrage opportunity due to technical buying, making it an ideal pair trade with identical issues from the same company. On 02/09/2025, we recommended CTA-B for our investment-grade long-duration portfolio. On 02/10/2025, technical high-volume buying in CTA-A turned our initial investment idea into a pair trade. This pair trade highlights how technical factors can create profitable opportunities in fixed-income securities, especially among identical issues from the same issuer. Read the full article on Seeking AlphaSeeking Alpha • Feb 09
CTA.PR.B: An Undervalued Investment-Grade Opportunity From Corteva
Summary CTA-B offers a 6.32% current yield, making it an attractive investment-grade preferred stock with solid financial backing from Corteva, Inc. Corteva, Inc.'s strong financial health and low leverage ensure the safety of uninterrupted dividend distributions for CTA-B shareholders. Comparative analysis shows CTA-B is undervalued, offering a potential 10% capital appreciation relative to its peers and Corteva's OTC bonds. Corteva's BBB credit rating and low-risk perception in the bond market further reinforce the security and value of investing in CTA-B. Read the full article on Seeking AlphaSeeking Alpha • Jan 10
Corteva: A Wide-Moat Play On Commodity Prices
Summary Corteva is a strong defensive play for stagflation with its wide economic moat in seeds, providing exposure to agricultural commodities and a growing dividend. The company has shown impressive performance since its 2019 spin-off, with growth in gross profits and operating income exceeding revenue growth, reflecting strong operating efficiency. Corteva faces risks such as regulatory and ESG concerns, pricing pressure in crop protection, and currency fluctuations, but remains a resilient and diversified investment. I rate Corteva a "Buy" for its defensive characteristics, allowing investors to gain commodity exposure as a best-in-breed operator. Read the full article on Seeking AlphaRendement pour les actionnaires
| CTVA | US Chemicals | US Marché | |
|---|---|---|---|
| 7D | 3.9% | -0.2% | -2.5% |
| 1Y | 9.9% | 6.8% | 20.1% |
Rendement vs Industrie: CTVA a dépassé le secteur US Chemicals qui a rapporté 6.8 % au cours de l'année écoulée.
Rendement vs marché: CTVA a sous-performé le marché US qui a rapporté 20.1 % au cours de l'année écoulée.
Volatilité des prix
| CTVA volatility | |
|---|---|
| CTVA Average Weekly Movement | 2.9% |
| Chemicals Industry Average Movement | 6.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Cours de l'action stable: CTVA n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de CTVA ( 3% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1802 | 21,500 | Chuck Magro | www.corteva.com |
Corteva, Inc. opère dans le secteur de l'agriculture. L'entreprise opère à travers deux segments, les semences et la protection des cultures. Le segment des semences développe et fournit du matériel génétique et des caractères avancés qui permettent d'obtenir un rendement optimal pour les exploitations agricoles.
Corteva, Inc. Résumé des fondamentaux
| CTVA statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$53.57b |
| Bénéfices(TTM) | US$1.25b |
| Recettes(TTM) | US$17.89b |
43.6x
Ratio P/E3.1x
Ratio P/SLe site CTVA est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| CTVA compte de résultat (TTM) | |
|---|---|
| Recettes | US$17.89b |
| Coût des recettes | US$9.20b |
| Marge brute | US$8.69b |
| Autres dépenses | US$7.44b |
| Les revenus | US$1.25b |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
Jul 30, 2026
| Résultat par action (EPS) | 1.87 |
| Marge brute | 48.56% |
| Marge bénéficiaire nette | 7.00% |
| Ratio dettes/capitaux propres | 13.6% |
Quelles ont été les performances à long terme de CTVA?
Voir les performances historiques et les comparaisonsDividendes
0.9%
Rendement actuel des dividendes39%
Ratio de distributionAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/06/25 22:28 |
| Cours de l'action en fin de journée | 2026/06/25 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github, nous proposons également des guides pour apprendre à utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Corteva, Inc. est couverte par 35 analystes. 19 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| null null | Argus Research Company |
| Benjamin Theurer | Barclays |
| Aron Ceccarelli | Berenberg |